Navigation Links
Phosphagenics Announces Completion of Transdermal Patch Prototypes
Date:5/29/2009

- Oxycodone Successfully Delivered into the Bloodstream

- Data Demonstrates Sustained Release and Increased Blood Levels of Oxycodone

MELBOURNE, Australia, May 29 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH; OTCQX: PPGNY) today announced the successful completion of preclinical studies related to its patented TPM/oxycodone transdermal patch system. The results of the preclinical studies demonstrated that by incorporating TPM/oxycodone into innovative patch systems developed by Phosphagenics, the delivery of oxycodone was significantly increased when compared to the Company's TPM/oxycodone gel alone.

"The development of the proprietary transdermal patch systems is a major step in advancing the Company's TPM delivery platform technology," said Dr. Esra Ogru, Phosphagenics' Chief Operating Officer. "Patch systems extend the duration of drug delivery, improve bioavailability, prevent environmental contamination, increase patient compliance and reduce the risk of potential abuse," she continued.

Phosphagenics has successfully developed both reservoir and matrix patches that contain TPM and oxycodone and produce sustained delivery. A reservoir patch is characterized by incorporating gels within the membrane, whereas matrix patches contain drugs in a solid form. The matrix patch is ideally suited for opioids such as oxycodone where abuse is an issue, as this makes it difficult to extract out of the matrix.

Oxycodone, a leading pain management drug, is currently administered either orally or intravenously. It is more potent than morphine with fewer side effects. Worldwide sales of oxycodone exceed $US1.5 billion. Phosphagenics aims to become the first company to provide chronic pain sufferers with a sustained-release transdermal system that delivers oxycodone into the bloodstream.

Previous preclinical and human clinical trials conducte
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
3. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
4. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
5. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
6. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
7. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
8. Medivation Announces Pricing of Public Offering
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... The College of New Rochelle announced ... the Mid-Hudson Region to be designated as a START-UP ... from qualified “high-technology” businesses that align with the College’s ... have been selected for the START-UP NY program and ... stimulate economic development in New York by growing business ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Kiadis,Pharma announced today that the U.S. Food ... Rhitol(TM) Orphan Drug Designation for the treatment ... complication of allogeneic,bone marrow transplantation is highly ... patient is unresponsive to steroid treatment.,Rhitol(TM) has ...
... PHILADELPHIA, Pennsylvania, April 15, THIS ANNOUNCEMENT IS AN ... SUBSCRIBE FOR OR PURCHASE ANY,SECURITIES REFERRED TO IN ... BE CONTAINED IN THE PROSPECTUS EXPECTED TO BE ... SCHEME. THE PROSPECTUS WILL,BE PUBLISHED AND MADE AVAILABLE ...
... ... Session -, SAN FRANCISCO and ... that data from an ongoing,Phase 1-2 clinical trial showed that the Company,s ... (PSA), a marker of tumor growth, in the lowest expanded dose group,tested ...
Cached Biology Technology:Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA 2Shire to Introduce a New UK Listed Holding Company 2Shire to Introduce a New UK Listed Holding Company 3Shire to Introduce a New UK Listed Holding Company 4Shire to Introduce a New UK Listed Holding Company 5Shire to Introduce a New UK Listed Holding Company 6Shire to Introduce a New UK Listed Holding Company 7Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 3
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... have hypothesized that the fetus can be exposed to ... the mother has been exposed, and this may have ... eczema and asthma) later in an infant’s life. However ... to detect antigen-specific T cells in cord blood. Recently, ...
... discovered 24 species believed to be new to science, ... amphibians, fish and insects. , Presented in a report ... led by Conservation International’s Rapid Assessment Program (RAP) and ... exploring unknown regions such as Suriname’s rainforest to assess ...
... dormant bacterial spores, researchers have revealed through atomic force ... cell wall that accompany the transformation from a spore ... Bacillus (rod-shaped bacteria) cells initiate a series of genetic, ... of metabolically dormant spores. They can remain dormant for ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Researchers track how spores break out of dormant state 2
... ELx50 is a fast and versatile automated ... our patented Dual-ActionTM 16-channel manifold. This breakthrough ... dispense and aspiration manifolds for overfill washing ... 384-well formats. The problem of fitting dispense ...
... The HybArray 12™ is an automated ... microarrays. The system automates both the hybridization ... onto glass slides. A single instrument can ... time in pairs and has multi-protocol software, ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: